Amer Oriental Plans To Buy Changchun Xinan Pharm For $30M (China)
This article was originally published in PharmAsia News
Executive Summary
American Oriental Bioengineering Inc. has signed a letter of intent to acquire Changchun Xinan Pharmaceutical Group Co., a privately owned plant-based pharmaceutical company, for up to about $30 million. American Oriental, which is based in China, said it has 90 days to enter into a definitive purchase agreement and close the transaction. American Oriental says the transaction is consistent with its acquisition strategy to acquire companies that are accretive to its operations within one year of closing. (Click here for more - May Require Paid Subscription